COX-2 inhibitor safety labels
Executive Summary
FDA issues "approvable" letter April 6 for Merck's Vioxx (rofecoxib) for the inclusion of updated gastrointestinal safety data in labeling. Pharmacia/Pfizer's Celebrex (celecoxib) receives "approvable" letter April 12. FDA's Arthritis Advisory Committee recommended Feb. 7-8 that Vioxx and Celebrex could incorporate GI safety data in product labels (1"The Pink Sheet" Feb. 19, p. 11)
You may also be interested in...
Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study
Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.
COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says
The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.
Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study
Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.